PubMed Health⌕ Search

Biomedical subjects

P Matejtschuk

Publications and source records attributed to P Matejtschuk.

11 recordsLinked to original sources
PubMed2002

A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma.

BACKGROUND AND OBJECTIVES: Intravenous immunoglobulin (IVIG) is used in a range of immunodeficiency states that require a broad spectrum of protective antibodies to a range of common pathogens. A comparison of the antigen-specific antibody profile of preparations of an IVIG (Vigam) derived from US and UK sourced plasma was performed, and these preparations were also compared with three other IVIG products from different manufacturers. MATERIALS AND METHODS: Antibodies against a range of bacterial and viral pathogens were measured by immunoassay. RESULTS: Similar profiles were found for Vigam made from UK and US source plasma and also for the other three IVIGs tested, but some specific differences were observed. CONCLUSIONS: IVIG preparations have a similar therapeutic spectrum of antibodies when prepared from plasma sourced either from the UK or the US.

Antibodies, Bacterial↗
PubMed2001

Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injection.

BACKGROUND AND OBJECTIVES: The tolerability and pharmacokinetics of a solvent/detergent-treated intramuscular immunoglobulin were compared with those of the standard product. MATERIALS AND METHODS: Single, 750-mg intramuscular (i.m.) injections were administered to a total of 36 healthy individuals: 23 in a double-blind trial and 13 in an open trial. Changes in specific serum hepatitis A and hepatitis B antibodies were monitored for a period of up to 3 months postinjection. RESULTS: No serious adverse reactions were reported, and the bioavailability of the solvent/detergent-treated preparation was equivalent to that of the standard i.m. immunoglobulin. CONCLUSION: There is no evidence that solvent/detergent treatment alters the pharmacokinetics or tolerance of human normal immunoglobulin, but it offers additional assurance against potential virus transmission.

Adolescent↗
PubMed1999

Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects.

OBJECTIVE: To see if modifications to the processing of intravenous immunoglobulin to include a virus inactivation stage alter immunoglobulin G (IgG) resulting in hypotension in patients. METHODS: Clinical trials were done involving extensive patient monitoring during infusion: in vitro - testing for markers of hypotension, and in vivo - an animal model which closely simulates clinical use. RESULTS: No hypotensive response was seen in the animal model or clinical trial. CONCLUSIONS: The production process used does not damage IgG or create vaso-active kinins as the preparation was free of hypotensive effects.

Adolescent↗
PubMed1996

Fingerprinting of glycans as their 2-aminoacridone derivatives by capillary electrophoresis and laser-induced fluorescence.

Capillary electrophoresis and laser-induced fluorescence detection have been used to fingerprint the 2-aminoacridone derivatives of complex glycans released from bovine fetuin and human IgG monoclonal antibodies. The utility of this method in distinguishing between N- and O-linked oligosaccharides and in determining the presence of sialic acid residues in glycan mixtures at an early stage of analysis has been demonstrated.

Aminoacridines↗
PubMed1988

Red-cell IgM-antibody capture assay for the detection of Mycoplasma pneumoniae-specific IgM.

A red-cell IgM-antibody capture assay has been developed for detecting Mycoplasma pneumoniae-specific IgM, which is based on the adsorption or 'capture' of IgM from patients' sera onto so-called 'inagglutinable' bovine red cells, chemically linked with anti-human mu. When M. pneumoniae antigen is added to the system, the red cells agglutinate in the presence of M. pneumoniae-specific IgM. The test was compared with the mu-capture ELISA described by Wreghitt & Sillis (1985), and was found to give comparable results. The two tests had similar sensitivity and specificity and could detect M. pneumoniae-specific IgM for a similar time (up to 6 months) after proven M. pneumoniae infection. However, the red-cell antibody capture assay is a much more simple and rapid test, taking only 1 h to perform (compared to 24 h for mu-capture ELISA). The red-cell IgM-antibody capture assay is therefore amenable to rapid diagnosis of M. pneumoniae infection and the institution of early appropriate antibiotic therapy.

Antibodies, Bacterial↗
PubMed1988

Experimental studies on red cell-based assays for total IgE and allergen-specific IgE.

The potential of red cell-based assays for IgE and allergen-specific IgE has been examined using mouse monoclonal anti-human IgE antibodies and chimaeric human IgE anti-4-hydroxy-3-iodo-5-nitrophenacetyl. Experiments concerned with developing a red cell IgE antibody-capture assay for allergen-specific IgE have pointed to the advantages of presenting the allergen on a second agglutinable red cell.

Allergens↗
PubMed1987

Isolation of low-frequency class-switch variants from rat hybrid myelomas.

Class-switch variants have been isolated from rat-rat hybrid myelomas by sib selection using a simple assay based on red cell-labelled antiglobulins. The variants detected are consistent with the gene order deduced from molecular cloning. They appear to arise spontaneously at a rate approximately ten-fold lower than for mouse cell lines but the rate of switching back to the parental isotype is substantial in comparison. An IgG2b variant antibody having the same specificity as CAMPATH-1 for human lymphocytes and monocytes is active in antibody-dependent cell-mediated killing (unlike the parental IgG2a) and may prove to be a valuable therapeutic antibody for immunosuppression and treatment of leukaemia and lymphoma.

Animals↗